| ANIMAL | evidence | Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation. | Tirzepatide | animal | 2025-12-13 |
| ANIMAL | evidence | Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain. | Tirzepatide | Weight & fat loss · animal | 2025-12-01 |
| ANIMAL | evidence | Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors. | Tirzepatide | Gut barrier & GI healing · animal | 2025-12-01 |
| ANIMAL | evidence | Tirzepatide improves extracellular matrix integrity and vascularization in pancreatic islets of a mouse model of obesity, diabetes, and menopause. | Tirzepatide | Weight & fat loss · animal | 2025-11-19 |
| ANIMAL | evidence | Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis. | Tirzepatide | Inflammation · animal | 2025-10-01 |
| ANIMAL | evidence | Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice. | LY3298176 | Fatigue & energy · animal | 2025-04-29 |
| ANIMAL | evidence | Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice. | LY3298176 | animal | 2024-09-01 |
| ANIMAL | evidence | GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. | LY3298176 | Weight & fat loss · animal | 2021-06-15 |
| ANIMAL | evidence | Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. | LY3298176 | Glycemic control · animal | 2020-09-03 |
| PRECLINICAL | evidence | Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study. | Tirzepatide | Weight & fat loss | 2026-12-01 |
| PRECLINICAL | evidence | Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. | Tirzepatide | Glycemic control | 2026-12-01 |
| PRECLINICAL | evidence | Lead-guided prodrug development of small molecules as GLP-1R agonists. | Tirzepatide | — | 2026-09-15 |
| PRECLINICAL | evidence | Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan. | Tirzepatide | — | 2026-09-01 |
| PRECLINICAL | evidence | Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study. | Tirzepatide | Glycemic control | 2026-08-15 |
| PRECLINICAL | evidence | The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Beyond weight loss: How metabolism in human adipocytes is shaped by GLP-1R agonists and dual GIPR/GLP-1R agonists. | Tirzepatide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Weight Loss Medications in Youth: Decision-Making Experiences, Eating Behaviors, and Uncertainty About Endpoint. | Tirzepatide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response? | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Papular granuloma annulare associated with tirzepatide: A case report. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Clinical Potential of GIP in Type 2 Diabetes and Obesity. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk. | Tirzepatide | Skin appearance & aging | 2026-08-01 |
| PRECLINICAL | evidence | Interpreting Lean Mass Changes During Tirzepatide-Induced Weight Loss: Beyond Quantitative Metrics. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE(-/-) mice. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model. | Tirzepatide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Beyond weight loss: multisystem benefits of obesity medications. | Tirzepatide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk. | Tirzepatide | — | 2026-08-01 |
| PRECLINICAL | evidence | GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology. | Tirzepatide | Glycemic control | 2026-08-01 |
| PRECLINICAL | evidence | Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations. | Tirzepatide | — | 2026-07-27 |
| PRECLINICAL | evidence | Accidental intradermal injection of tirzepatide associated with increased adverse events. | Tirzepatide | — | 2026-07-27 |
| PRECLINICAL | evidence | Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis. | Tirzepatide | — | 2026-07-25 |
| PRECLINICAL | evidence | Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report. | Tirzepatide | — | 2026-07-24 |
| PRECLINICAL | evidence | One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy. | Tirzepatide | — | 2026-07-23 |